The Lancet Gastroenterology and Hepatology
Fecha de publicación: 1 november 2018
Autores: Prof Raja Atreya, MD., Prof Markus F Neurath, MD.
Background: Biological therapy has led to marked improvements in treatment of patients with inflammatory bowel disease, and an increasing number of drugs has been approved for treatment. However, only a subgroup of patients responds to therapy, highlighting the need to identify biomarkers for therapeutic response to allow personalised medicine in inflammatory bowel disease.